Lv41
558 积分 2025-05-27 加入
Structural perspectives on the androgen receptor, the elusive shape-shifter
12天前
已完结
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial
1个月前
已完结
Optimizing treatment for metastatic castration‐resistant prostate cancer: Food and Drug Administration‐approved therapies, emerging strategies, and biomarker‐driven approaches
1个月前
已完结
Therapeutic Strategies to Target the Androgen Receptor
1个月前
已完结
Bioanalysis for PK for antibody drug conjugates using ligand binding assay–challenges and bioanalytical strategies
1个月前
已完结
Application of new approach methodologies for nonclinical safety assessment of drug candidates
1个月前
已完结
Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies
1个月前
已完结
Antibody–drug conjugates come of age in oncology
1个月前
已完结
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer
1个月前
已完结
Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells
1个月前
已完结
皖公网安备34019202002308
